
Organic Process Research and Development p. 387 - 398 (2017)
Update date:2022-09-26
Topics:
Linghu, Xin
Wong, Nicholas
Iding, Hans
Jost, Vera
Zhang, Haiming
Koenig, Stefan G.
Sowell, C. Gregory
Gosselin, Francis
The process development of a synthetic route to manufacture ERK inhibitor GDC-0994 on multikilogram scale is reported herein. The API was prepared as the corresponding benzenesulfonate salt in 7 steps and 41% overall yield. The synthetic route features a biocatalytic asymmetric ketone reduction, a regioselective pyridone SN2 reaction, and a safe and scalable tungstate-catalyzed sulfide oxidation. The end-game process involves a telescoped SNAr/desilylation/benzenesulfonate salt formation sequence. Finally, the development of the API crystallization allowed purging of process-related impurities, obtaining >99.5A% HPLC and >99% ee of the target molecule.
Beijing Harmony Chemical Co., Ltd.
Contact:86-010-84956928
Address:Room 207, Jin feng he B building, No 8 Xin Jie Kou Wai Street, Xi Cheng District, Beijing,PRC. 10008
Shandong Jiulong Hisince Pharmaceutical Co.,Ltd.
Contact:--
Address:Huadian Pioneer Park, Huadian Township, Qihe County, Dezhou City, Shandong, P.R.China
Shenzhen JYMed Technology Co.,Ltd.
website:http://www.jymedtech.com
Contact:+86-755-26612112
Address:1#8,9/F, Biomedicine innovation Industrial Park, No.14, Jinhui Road, Pingshan Sistrict, Shenzhen, China
Contact:+86-27-87204219, +86-27-87215023
Address:2402, HuiGu Space-time Building, 8 Forest Road, East Lake Hi-Tech Development Zone
Hubei Lansun Biochemical Pharmaceutical Co., Ltd
Contact:714-6395977
Address:No. 81 Pengcheng Avenue, economic and technological development zone, Huangshi City, Hubei Province,China
Doi:10.1002/adsc.201300419
(2013)Doi:10.1016/j.cplett.2013.08.029
(2013)Doi:10.1002/chem.201300817
(2013)Doi:10.1021/jacs.0c07381
(2020)Doi:10.1021/ja00978a026
(1967)Doi:10.1016/0040-4039(93)89012-F
(1993)